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Dlipoproteins were collected at DCCT baseline (1983–89) and were
correlated with common and internal carotid IMT determined by
ultrasonography during the observational follow-up of the DCCT, the
Epidemiology of Diabetes Interventions and Complications (EDIC)
study, at EDIC ‘Year 1’ (199–1996) and EDIC ‘Year 6’ (1998–2000). This
article contains data on the associations of DCCT baseline lipoprotein
proﬁles (NMR-based VLDL & chylomicrons, IDL/LDL and HDL sub-
classes and ‘conventional’ total, LDL-, HDL-, non-HDL-cholesterol and
triglycerides) with carotid IMT at EDIC Years 1 and 6, stratiﬁed by
gender. The data are supplemental to our original research article
describing detailed associations of DCCT baseline lipids and lipoprotein
proﬁles with EDIC Year 12 carotid IMT (Basu et al. in press) [1].
& 2015 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations TableSubject area Biologyore speciﬁc sub-
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acquiredNMR, Ultrasound readingata format Analyzed
xperimental
factorsEDIC Years 1 and 6 after intensive or conventional diabetes management in
DCCT vs DCCT baselinexperimental
featuresLipoprotein subclasses and conventional lipids at DCCT baseline correlated
with carotid IMT in follow-up yearsata source
locationDCCT/EDIC centers (USA, Canada)ata accessibility Within the Data in Brief articleD
Value of the data
 Previously unreported longitudinal associations of baseline lipoprotein subclasses with carotid IMT
at two follow-up time-points in a large well-characterized cohort of people with T1DM.
 May stimulate further research on the clinical utility of lipoprotein subclasses as prognostic mar-
kers for cardiovascular disease in diabetes.
 May facilitate new therapies to target lipids and lipoprotein classes signiﬁcantly associated with
vascular events in diabetes.1. Data
The Diabetes Control and Complications Trial (DCCT) examined the effects of intensive diabetes
management on the development and progression of diabetic retinopathy [2]. The cohort comprised
1441 T1DM patients aged 13–39 years who were free of overt cardiovascular disease (CVD) at
enrollment in 1983–89. In 1994, the Epidemiology of Diabetes Interventions and Complications Trial
(EDIC), a longitudinal observational phase of DCCT was initiated to assess the long-term effects of the
DCCT intervention on cardiovascular and related complications [3]. Carotid IMT data were obtained at
EDIC ‘Years’ 1 (1994–1996), 6 (1998–2000), and 12 (2004–2006). In addition to conventional lipids,
nuclear magnetic resonance (NMR)-determined lipoprotein subclasses have been predictive of CVD in
A. Basu et al. / Data in Brief 6 (2016) 33–38 35some T1DM studies [4–6], and were analyzed in this cohort to examine associations with a surrogate
of CVD: common and internal carotid IMT.
The baseline characteristics of the participants have been described previously [1]. Table 1 shows data
on the associations of DCCT baseline standard lipid proﬁles and NMRLSP with common carotid IMT in
men and women at EDIC Years 1 and 6. Generally the data reveal positive associations of conventional
LDL-cholesterol and NMR-based total IDL/LDL with IMT, and inverse associations of NMR-based large and
medium VLDL subclasses, medium HDL and HDL particle size with IMT, most marked in men.
Table 2 shows data on the associations of DCCT baseline standard lipid proﬁles and NMR-LSP with
internal carotid IMT in men and women at EDIC Years 1 and 6. Generally there are positiveTable 1
DCCT baseline lipoprotein proﬁles vs. common carotid IMT-EDIC Years 1 and 6 (standardized linear regression
coefﬁcientsa).
Variables Men (n¼244) Women (n¼208)
Year 1 Year 6 Year 1 Year 6
NMR subclasses Slope (SE) P Slope (SE) P Slope (SE) P Slope (SE) P
Total VLDL and chylomicrons
(nmol/L)
0.02 (0.06) 0.74 0.04
(0.05)
0.42 0.05
(0.07)
0.43 0.08
(0.07)
0.22
Large VLDL and chylomicrons
(nmol/L)
0.12
(0.06)
0.04 0.04
(0.05)
0.48 0.01 (0.07) 0.9 0.1 (0.07) 0.14
Medium VLDL (nmol/L) 0.13
(0.05)
0.02 0.05
(0.05)
0.35 0.04
(0.07)
0.63 0.02
(0.08)
0.78
Small VLDL (nmol/L) 0.11 (0.06) 0.049 0.02
(0.05)
0.64 0.05
(0.06)
0.43 0.08
(0.06)
0.22
Total IDL/LDL (nmol/L) 0.12 (0.06) 0.04 0.15 (0.05) 0.005 0.12 (0.06) 0.04 0.07 (0.07) 0.33
IDL (nmol/L) 0.06
(0.06)
0.30 0.04
(0.05)
0.42 0.06
(0.06)
0.32 0.06 (0.06) 0.36
Large LDL (nmol/L) 0.04 (0.06) 0.48 0.06 (0.05) 0.24 0.14 (0.06) 0.03 0.04 (0.07) 0.57
Small LDL (nmol/L) 0.09 (0.05) 0.1 0.1 (0.05) 0.06 0.09
(0.07)
0.17 0.01 (0.07) 0.90
Total HDL (lmol/L) 0.08
(0.06)
0.20 0.01
(0.06)
0.87 0.10 (0.06) 0.08 0.02 (0.06) 0.74
Large HDL (mmol/L) 0.11
(0.06)
0.08 0.05
(0.06)
0.45 0.16 (0.06) 0.01 0.05 (0.07) 0.46
Medium HDL (mmol/L) 0.15
(0.07)
0.02 0.03
(0.06)
0.66 0.004
(0.05)
0.94 0.03
(0.05)
0.62
Small HDL (mmol/L) 0.1 (0.06) 0.09 0.04
(0.06)
0.52 0.04
(0.06)
0.55 0.03 (0.06) 0.59
NMR particle diameter
VLDL particle size (nm) 0.18
(0.06)
0.001 0.03
(0.05)
0.64 0.05 (0.07) 0.51 0.001
(0.07)
0.98
LDL particle size (nm) 0.05
(0.05)
0.39 0.04
(0.05)
0.46 0.06 (0.07) 0.41 0.01 (0.07) 0.85
HDL particle size (nm) 0.15
(0.06)
0.01 0.10
(0.06)
0.08 0.14 (0.07) 0.04 0.06 (0.07) 0.36
Conventional lipids
Total cholesterol (mg/dl) 0.05 (0.06) 0.41 0.08 (0.05) 0.13 0.06
(0.06)
0.34 0.03 (0.07) 0.63
Triglyceride (mg/dl) 0.07
(0.05)
0.14 0.07 (0.05) 0.11 0.15
(0.09)
0.08 0.15
(0.09)
0.11
LDL–cholesterol (mg/dl) 0.11 (0.06) 0.04 0.10 (0.05) 0.049 0.01 (0.07) 0.90 0.02 (0.07) 0.76
Non–HDL–cholesterol (mg/dl) 0.07 (0.06) 0.22 0.09 (0.05) 0.09 0.02
(0.07)
0.75 0.001
(0.07)
0.92
HDL–cholesterol (mg/dl) 0.07
(0.07)
0.30 0.02
(0.06)
0.72 0.18 (0.06) 0.003 0.08 (0.06) 0.18
P values in bold if signiﬁcant (o0.05).
a Models were adjusted for DCCT randomization, albumin excretion rate, HbA1C, diabetes duration, body mass index,
and current smoking at DCCT baseline (1983–89). The regression models were also adjusted for statin use (any time during
the DCCT baseline to EDIC year 12), ultrasound devices, and image readers at EDIC year 1 and 6 respectively.
Table 2
DCCT baseline lipoprotein proﬁles vs. internal carotid IMT-EDIC Years 1 and 6 (standardized linear regression coefﬁcientsa).
Variables Men (n¼242) Women (n¼203)
Year 1 Year 6 Year 1 Year 6
NMR subclasses Slope (SE) P Slope (SE) P Slope (SE) P Slope (SE) P
Total VLDL and chylomicrons
(nmol/L)
0.01 (0.07) 0.92 0.03
(0.07)
0.67 0.01 (0.06) 0.83 0.06 (0.07) 0.35
Large VLDL and chylomicrons
(nmol/L)
0.04 (0.07) 0.55 0.07
(0.07)
0.33 0.003
(0.07)
0.97 0.05 (0.07) 0.50
Medium VLDL (nmol/L) 0.07 (0.07) 0.28 0.02 (0.07) 0.80 0.04 (0.07) 0.57 0.01 (0.07) 0.84
Small VLDL (nmol/L) 0.05 (0.07) 0.51 0.04
(0.07)
0.55 0.001 (0.06) 0.99 0.06 (0.06) 0.33
Total IDL/LDL (nmol/L) 0.23 (0.07) 0.002 0.14 (0.07) 0.06 0.004 (0.06) 0.95 0.02
(0.06)
0.74
IDL (nmol/L) 0.09 (0.07) 0.22 0.004
(0.07)
0.96 0.08 (0.06) 0.18 0.09 (0.06) 0.13
Large LDL (nmol/L) 0.02 (0.07) 0.75 0.03 (0.07) 0.61 0.002
(0.06)
0.97 0.04
(0.06)
0.52
Small LDL (nmol/L) 0.14 (0.07) 0.04 0.09 (0.07) 0.21 0.03 (0.07) 0.65 0.03 (0.07) 0.65
Total HDL (lmol/L) 0.09 (0.08) 0.26 0.07 (0.08) 0.38 0.02 (0.05) 0.67 0.09
(0.06)
0.12
Large HDL (mmol/L) 0.04 (0.08) 0.63 0.07
(0.08)
0.42 0.03 (0.06) 0.62 0.03
(0.06)
0.56
Medium HDL (mmol/L) 0.10 (0.08) 0.23 0.02 (0.08) 0.79 0.03 (0.05) 0.52 0.06
(0.05)
0.23
Small HDL (mmol/L) 0.20 (0.08) 0.01 0.09 (0.08) 0.26 0.001 (0.06) 0.99 0.001
(0.06)
0.99
NMR particle diameter
VLDL particle size (nm) 0.0001
(0.07)
1.00 0.06
(0.07)
0.44 0.03 (0.07) 0.66 0.02 (0.07) 0.75
LDL particle size (nm) 0.08 (0.07) 0.25 0.03
(0.07)
0.63 0.02 (0.07) 0.75 0.02 (0.06) 0.71
HDL particle size (nm) 0.13 (0.08) 0.08 0.06 (0.07) 0.35 0.07 (0.06) 0.29 0.12 (0.08) 0.11
Conventional lipids
Total cholesterol (mg/dl) 0.17 (0.07) 0.02 0.13 (0.07) 0.07 0.15 (0.06) 0.01 0.05 (0.06) 0.44
Triglyceride (mg/dl) 0.02 (0.06) 0.76 0.04 (0.06) 0.51 0.04 (0.09) 0.64 0.06 (0.09) 0.52
LDL–cholesterol (mg/dl) 0.17 (0.07) 0.02 0.14 (0.07) 0.05 0.12 (0.06) 0.05 0.04 (0.06) 0.51
Non–HDL–cholesterol (mg/dl) 0.16 (0.07) 0.03 0.12 (0.07) 0.09 0.12 (0.06) 0.05 0.05 (0.07) 0.45
HDL–cholesterol (mg/dl) 0.05 (0.08) 0.57 0.04 (0.08) 0.62 0.09 (0.06) 0.12 0.01 (0.06) 0.87
P values in bold if signiﬁcant (o0.05).
a Models were adjusted for DCCT randomization, albumin excretion rate, HbA1C, diabetes duration, body mass index, and
current smoking at DCCT baseline (1983–89). The regression models were also adjusted for statin use (any time during the
DCCT baseline to EDIC year 12), ultrasound devices, and image readers at EDIC year 1 and 6 respectively.
A. Basu et al. / Data in Brief 6 (2016) 33–3836associations of conventional total, LDL- and non-HDL cholesterol levels with IMT in both men and
women, and of NMR-based total IDL/LDL, small LDL and HDL (small)-subclasses with IMT in men only.
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) provides access to the
raw data from the DCCT/EDIC study through the NIDDK Central Repository (https://www.niddkre
pository.org/home/). This website includes information regarding the data sets that are available, and
details of the data request, review, and approval process.2. Experimental design, materials and methods
2.1. Study subjects
The original DCCT cohort comprised 1441 T1DM participants aged 13–39 years at study entry
(1983–1989). They had no dyslipidemia or hypertension and were randomly assigned to conventional
A. Basu et al. / Data in Brief 6 (2016) 33–38 37(n¼730) or intensive (n¼711) diabetes treatment [2]. The data included in this article are derived
from a sub-set of DCCT participants with available common and internal carotid IMT measurements
at EDIC Years 1 and 6. The study was approved by the Institutional Review Boards of MUSC, University
of Oklahoma Health Sciences Center (OUHSC), and all participating DCCT/EDIC centers, and written
informed consent was obtained from all subjects.
2.2. Ultrasonography and image analysis
Common and internal carotid IMT measurements in EDIC have previously been described in detail
[7]. Reliability measures for IMT readers at EDIC Years 1 and 6 have been reported previously [8]. In
the current sub-study, we examined the longitudinal associations between lipoprotein proﬁles at
DCCT entry (1983–89) and common and internal carotid IMT at EDIC Years 1 and 6.
2.3. NMR Lipoprotein subclass analysis
NMR-LSP was determined in ﬁrst-thaw serum specimens (250 mL) using a 400-MHz proton NMR
analyzer at LipoScience Inc. (Raleigh, NC, USA) as described [9]. Lipoprotein subclasses were
expressed as molar particle concentrations and deﬁned by particle diameter: VLDL subclasses (large:
60–200 nm; medium: 35–59 nm; small: 27–34 nm), intermediate density lipoprotein (IDL) (23–
37 nm), LDL subclasses (large: 21.3–23 nm; small: 18.3–21.2 nm), HDL subclasses (large: 8.9–13 nm;
medium: 8.3–8.8 nm; small: 7.3–8.2 nm). Average VLDL, LDL, and HDL particle sizes (nm) were
determined by weighting the relative mass percentage of each subclass by its diameter.
2.4. DCCT baseline conventional lipid proﬁles, HbA1c, and other clinical measurements
Total cholesterol, triglyceride, and HDL-C levels were determined using previously reported
enzymatic methods [10]. LDL-C was estimated according to the Friedewald equation. HbA1c was
measured by high-performance ion exchange liquid chromatography [11].
2.5. Statistical analysis
Multiple regression analyses were performed to examine correlations of conventional lipids and
NMR-LSP at DCCT baseline with common and internal carotid IMT at EDIC Years 1 and 6, stratiﬁed by
gender. Each lipid/lipoprotein measure was included as an independent variable in the linear model
simultaneous with a ﬁxed group of covariates that were measured at DCCT baseline: diabetes
duration, smoking (yes/no), DCCT treatment group, body mass index (BMI), urinary albumin excretion
rate (AER), and HbA1c, statin use and ultrasound imaging device. Two-tailed po0.05 was considered
to be statistically signiﬁcant. Data were analyzed using SAS/STAT software (Version 9.2; SAS Institute
Inc., Cary, NC).Acknowledgments
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